Marboxidin 5 mg Chewable Tablets for Dogs and Cats

País: Regne Unit

Idioma: anglès

Font: VMD (Veterinary Medicines Directorate)

Compra'l ara

Fitxa tècnica Fitxa tècnica (SPC)
20-07-2021

ingredients actius:

Marbofloxacin

Disponible des:

Lavet Pharmaceuticals Ltd

Codi ATC:

QJ01MA93

Designació comuna internacional (DCI):

Marbofloxacin

formulario farmacéutico:

Chewable tablet

tipo de receta:

POM-V - Prescription Only Medicine – Veterinarian

Grupo terapéutico:

Cats, Dogs

Área terapéutica:

Antimicrobial

Estat d'Autorització:

Expired

Data d'autorització:

2013-03-08

Fitxa tècnica

                                Issued: March 2013
AN: 00449/2012
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Marboflox 5 mg Chewable Tablets for Dogs and Cats
_(in Czech Republic, Hungary, Poland,)_
Marboxidin 5 mg Chewable Tablets for Dogs and Cats
_(in Belgium, France, Germany, Ireland, Luxembourg, Netherlands,
Spain, United Kingdom)_
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE:
Marbofloxacin
5 mg
EXCIPIENTS:
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Chewable tablet.
Brownish, oval, divisible, centre scored chewable tablets.
The tablets can be divided into equal halves.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs and cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In dogs
Marbofloxacin is indicated in the treatment of:

skin and soft tissue infections (skinfold pyoderma, impetigo,
folliculitis, furunculosis,
cellulitis) caused by strains of microorganisms susceptible to
marbofloxacin_;_

urinary tract infections (UTI) associated or not with prostatitis or
epididymitis caused by
strains of microorganisms susceptible to marbofloxacin_;_

respiratory
tract
infections
caused
by
strains
of
microorganisms
susceptible
to
marbofloxacin_._
In cats
Marbofloxacin is indicated in the treatment of skin and soft tissue
infections (wounds,
abscesses,
phlegmons)
and
upper
respiratory
tract
infections
caused
by
strains
of
microorganisms susceptible to marbofloxacin.
4.3
CONTRAINDICATIONS
Do not use in dogs aged less than 12 months, or less than 18 months
for exceptionally large
breeds of dogs, such as Great Danes, Briard, Bernese, Bouvier and
Mastiffs, with a longer
growth period. Not recommended for use in cats aged less than 16
weeks.
Do
not
use
in
animals
with
known
hypersensitivity
to
marbofloxacin
or
other
(fluoro)quinolones.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
A low urinary pH could have an inhibitory effect on the activity of
marbofloxacin.
Issued: March 2013
AN: 00449/2012
Page 2 of 4
4.5
SPECIAL PRECAUT
                                
                                Llegiu el document complet
                                
                            

Cerqueu alertes relacionades amb aquest producte